ELVESYS

Their core work

Elvesys is a Paris-based SME that designs and manufactures microfluidic instruments and organ-on-chip systems for life science research and pharmaceutical testing. They provide the hardware and expertise that lets research teams build lab-on-a-chip devices, automate cell culture workflows, and run high-throughput screening experiments. Their technology underpins applications ranging from personalized medicine and disease modeling to soft robotics and agricultural diagnostics. With 46 H2020 projects and EUR 9.2M in EC funding, they function as a key technology supplier embedded across dozens of European research consortia.

What they specialise in

How they've shifted over time

In their early H2020 period (2014–2018), Elvesys focused on establishing microfluidics as a platform for biomedical diagnostics — biomarker detection, disease screening (schizophrenia, tuberculosis), and thermal management, while launching their first organ-on-chip projects. From 2019 onward, their keyword profile shifted dramatically toward bioprinting, origins of life, protocells, artificial life, and soft robotics, indicating a pivot from purely diagnostic applications toward fundamental biology and bio-inspired engineering. This evolution shows a company that has matured its core microfluidic technology and is now pushing it into frontier science domains where few commercial players operate.

Elvesys is expanding from a microfluidics hardware supplier into a platform company serving frontier biology — expect them to pursue protocell, bioprinting, and artificial life collaborations next.

How they like to work

Elvesys operates in a dual mode: they coordinate their own focused projects (15 as coordinator, mostly MSCA fellowships and SME instruments worth EUR 85K–196K each) while embedding as a technology partner in large research consortia (30 as participant). With 286 unique partners across 48 countries, they are clearly a hub — not locked into repeat partnerships but sought after by diverse groups needing microfluidic infrastructure. This makes them easy to integrate into new consortia; they are accustomed to multi-partner projects and bring plug-and-play technology rather than demanding scientific leadership.

Elvesys has built one of the broadest partner networks among microfluidics SMEs in Europe, with 286 unique consortium partners spanning 48 countries. Their reach extends well beyond France and Western Europe into a genuinely global collaboration footprint.

What sets them apart

Elvesys occupies a rare niche: a commercially active SME that manufactures microfluidic instruments AND actively participates in frontier research. Most microfluidics companies either sell equipment or do research — Elvesys does both, which means they understand real lab needs and can translate scientific requirements into working hardware. Their 48-country network and 46-project track record make them one of the most H2020-experienced microfluidics companies in Europe, offering consortium builders a partner who already knows how EU projects work and can deliver reliable technology contributions without hand-holding.

Highlights from their portfolio

• MOOAC
  Elvesys coordinated this Multi-compartmental Organ-on-a-Chip project, which exemplifies their core ambition to build complete organ simulation platforms for pharmaceutical testing.
• ACDC
  Their largest single funding (EUR 512K) for building artificial cells with distributed cores — marks their strategic move into synthetic biology and shows they can win substantial RIA funding.
• SoRoHuMI
  An unexpected application of their microfluidic expertise to soft robotic rehabilitation devices, demonstrating the versatility of their core technology beyond biomedical diagnostics.